V. Leblond
YOU?
Author Swipe
View article: PB1868 B‐CELL PROLYMPHOCYTIC LEUKEMIA (B‐PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS
PB1868 B‐CELL PROLYMPHOCYTIC LEUKEMIA (B‐PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS Open
Background: B‐PLL is a rare entity that was debated. It is now recognized in the WHO classification and defined by the presence of prolymphocytes in peripheral blood (PB) exceeding 55% of lymphoid cells, different from transformed chronic …
View article: PF387 FRENCH IBRUTINIB OBSERVATIONAL STUDY (FIRE): REAL‐WORLD STUDY OF IBRUTINIB TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN FRANCE
PF387 FRENCH IBRUTINIB OBSERVATIONAL STUDY (FIRE): REAL‐WORLD STUDY OF IBRUTINIB TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN FRANCE Open
Background: Ibrutinib is a first‐in‐class oral inhibitor of Bruton's tyrosine kinase approved for the treatment of adult patients (pts) with CLL. Single‐agent ibrutinib improved progression‐free survival (PFS) and overall survival (OS) vs …
View article: PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)
PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM) Open
Background: Anemia and fatigue can impair quality of life in patients (pts) with WM and are common reasons for the initiation of WM treatment. Ibrutinib, a first‐in‐class, once‐daily inhibitor of BTK, is approved in the EU for the treatmen…
View article: PF487 MAJOR RESPONSES IN MYD88 WILDTYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111)
PF487 MAJOR RESPONSES IN MYD88 WILDTYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) Open
Background: BTK inhibitors have been shown to be highly active in patients with WM harboring the MYD88 L265P mutation, however lower response rates and shorter survival have been reported in patients that lack such mutations (i.e MYD88 WT …
View article: A revised international prognostic score system for Waldenström’s macroglobulinemia
A revised international prognostic score system for Waldenström’s macroglobulinemia Open
Background: Waldenström's Macroglobulinemia (WM) is an indolent disease with variable clinical presentation and heterogeneous prognosis. A robust and validated staging system was developed a decade ago, however, since then the treatment of…
View article: 4CPS-136 Are cardiovascular adverse events with ibrutinib well considered?
4CPS-136 Are cardiovascular adverse events with ibrutinib well considered? Open
Background Chronic lymphocytic leukaemia and mantle cell lymphoma have a new standard of care: ibrutinib (metabolised by CYP3A4/5 and P-glycoprotein inhibitor). Cardiovascular (CV) adverse events are characterised by atrial fibrillation (A…
View article: A HEAD‐TO‐HEAD PHASE 3 STUDY COMPARING BGB‐3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
A HEAD‐TO‐HEAD PHASE 3 STUDY COMPARING BGB‐3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA Open
Introduction: Bruton's tyrosine kinase (BTK) is a critical component of the B-cell receptor signaling cascade. Inhibition of BTK has emerged as a promising strategy for targeting B-cell malignancies including Waldenström macroglobulinemia …